V2-20210630

COVID-19 Vaccine Administration

Non-Risk Based Payment

Neighborhood Health Plan of RI

Date Completed:

SFY 2021

Contract Start: 7/1/2020
Contract End: 6/30/2020
Contract Run-Out: 6/30/2021

Reporting From:
Reporting Through:

Total Requested Reimbursement: $ 127.66

							If Vaccine Site in Rhode Island:		If Vaccine Site Outside Rhode Island:				
Last Name	First Name	Medicaid ID	DOB	Age @ DOS	Date of Service	Location Type	Location Name	Municipality	OOS Location	OOS Municipal	OOS State	Vaccine Type	Reimbursement
L Name	F Name	MID	4/1/2004	16	3/1/2021	Pharmacy	CVS	Providence				Moderna Covid-19 Vaccine Administration – First Dose	$ 14.04
L Name	F Name	MID	4/1/2004	16	3/1/2021	State	Providence Site	Providence				Moderna Covid-19 Vaccine Administration – Second Dose	$ 14.04
L Name	F Name	MID	4/1/2000	20	3/2/2021	State	Providence Site	Providence				Moderna Covid-19 Vaccine Administration – First Dose	$ 8.16
L Name	F Name	MID	4/1/2000	20	3/3/2021	State	Providence Site	Providence				Moderna Covid-19 Vaccine Administration – Second Dose	$ 8.16
L Name	F Name	MID	4/1/2004	17	4/1/2021	State	Providence Site	Providence				Pfizer-Biontech Covid-19 Vaccine Administration – First Dos	$ 41.63
L Name	F Name	MID	4/1/2001	20	4/1/2021	Municipality	Westerly Site	Westerly				Janssen Pharmaceuticals - Johnson & Johnson - Single Dose	$ 41.63
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD
													TBD

			TBD
			TBD
			TBD

			TBD
			TBD
			TBD

			TBD
			TBD
			TBD

			TBD
			TBD
			TBD

			TBD
			TBD
			TBD

			TBD
			TBD
			TBD